CD274 and non-small cell lung carcinoma: These results showed that pembrolizumab could provide clinical benefit for patients with BMs, such that it has become the standard treatment in patients with advanced PD-L1–positive NSCLC, irrespective of BM status at baseline (Reck et al., 2016; Mansfield et al., 2019).